



## New Alzheimer's Risk Test to launch in the US & Canada

### Test provides an individual's risk of cognitive decline due to Alzheimer's from a saliva sample

Infinity BiologiX (IBX) will launch in early October, in the US and Canada, the IBX Alzheimer's Risk Test, powered by Cytox's *genoSCORE™* technology, with medical liaison and customer support from Vanguard Pharma. The test, for physician use only, can identify individuals most at risk of cognitive decline due to Alzheimer's disease decades before any symptoms arise.

The test analyses over 100,000 single nucleotide polymorphisms (SNPs) - common genetic variations - associated with Alzheimer's disease. Each of these SNPs either elevate or reduce the genetic risk of Alzheimer's, with the test analysing the full array of SNPs together to generate an individual's personal result.

Physicians can use the Alzheimer's Risk Test to identify patients most at risk of cognitive decline, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. The results of the test can guide lifestyle changes and use of drug therapy to delay the onset of disease symptoms.

The test will be provided by Infinity BiologiX (IBX) laboratories, powered by Cytox's *genoSCORE*

polygenic risk score technology, with Vanguard Pharma providing medical liaison and customer support.

**Dr. Richard Pither, CEO of Cytox** said: "Cytox, with its partners IBX and Vanguard Pharma, are bringing this test to physicians throughout the US and Canada. We're delighted to be working with the IBX team, which has an established track record of delivering diagnostic services. Our medical liaison team at Vanguard will be organising webinars, group meetings, and attending conferences - including **A4M Anti-Aging World Congress** in Las Vegas in November. If you would like to hear more about the test, please follow the contacts below."

For physicians in the US and Canada wanting to pre-register, to order the test in early October, please visit:

[www.alzheimers-risk-test.com](http://www.alzheimers-risk-test.com)

For physicians in the US and Canada interested in hearing more about the test, please contact:

[alzheimers@vanguardpharma.com](mailto:alzheimers@vanguardpharma.com)

For physicians in Europe please see

[www.genoscore-lab.com](http://www.genoscore-lab.com) for more information.

*Modifiable factors account for more than 40% of the risk for dementia<sup>1</sup>. Using this test physicians can understand their patients' future risk of disease progression to guide lifestyle advice and clinical management. The following chart shows the well-documented modifiable risk factors associated with Alzheimer's disease, and executable actions that patients can take to mitigate the risks, with the potential to delay the onset of symptoms, and slow disease progression.*



1. Lancet Commission: **Dementia prevention, intervention, and care: 2020**

Click this image  
to visit the  
Alzheimer's Risk Test  
web portal

Risk assessment in Alzheimer's disease

## AAIC 2021 presentations

### Enriching clinical studies with highest risk patients

**P**olygenic Risk Scoring, using the *genoSCORE* platform, can identify clinical study participants most likely to experience cognitive decline during the timescales of the trial. Such patients are ideal when seeking to observe the efficacy of drug therapy. This test only requires DNA from a saliva sample, and can screen out unsuitable candidates early in the recruitment process prior to more invasive and expensive procedures.

Furthermore, this approach is particularly powerful at identifying higher risk individuals who are cognitively normal APOE3 homozygotes, and who are considered low risk using existing methodologies. As such, patient recruitment using this test has the potential to broaden and enlarge the patient population suitable to receive

the investigational drugs, if approved. The full poster is available [here](#).

### First patient experience of test from Europe

In this case study, the *genoSCORE* test provided a valuable assessment of genetic risk for this individual who was concerned about his likelihood to decline cognitively towards AD and as such, contributed significantly to his personal action plan to mitigate the risks. The ease and effectiveness of home sampling of saliva as source DNA for the test was considered greatly beneficial and well aligned with the continuing need for remote consultations in the light of COVID-19 concerns. Further, larger-scale, studies to determine the full clinical and associated economic impact of the *genoSCORE* test are required. The full poster is available [here](#)

## World Alzheimer's Month

**T**here are over 50 million people worldwide with Alzheimer's disease, and that figure is set to double over the coming years. The financial burden of this disease already runs at over \$1 trillion a year, but the personal and familial emotional distress that Alzheimer's causes, to so many people, is incalculable. However, great progress is being made in the field, in understanding the fundamental mechanisms that define the disease, new clinical practice to managing patients, new diagnostic approaches, and new interventional drug therapies. At Cytos, we're proud to be a part of that progress, which is all directed at reducing the burden of Alzheimer's disease.

